AgingResearch.NewsJoin free

Vanqua Bio

CompanyUnited States

Wikidata

Vanqua Bio develops 2 assets, the furthest in phase 1 (VQ-101 in GBA-Parkinson’s). Mostly small molecule acting on GBA1 and C5AR1; based in the United States.

2
Assets
Furthest stage
Phase 1
Raised
US$130m
0
Trials
0
Signals

Pipeline

2

  • VQ-101

    Allosterically activates glucocerebrosidase (GCase).

    Phase 1, Small molecule, GBA1, GBA-Parkinson’s

  • VQ-201

    Antagonizes C5aR1 to reduce pathogenic complement-mediated inflammation.

    Preclinical, Small molecule, C5AR1, inflammatory disorder

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Funding rounds and grants2
  • People19
  • Similar companies6

Intelligence